A Phase 2a Trial of STNM01 by a Single Submucosal Injection to Investigate the Mucosal Healing Efficacy in Patients with Ulcerative Colitis

Trial Profile

A Phase 2a Trial of STNM01 by a Single Submucosal Injection to Investigate the Mucosal Healing Efficacy in Patients with Ulcerative Colitis

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs STNM 01 (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Stelic Institute & Co
  • Most Recent Events

    • 01 Nov 2017 Primary endpoint (Improvement of endoscopic lesions with respect to Mucosal healing by Mayo Endoscopic Subscore: STNM01 (250 nM) group versus placebo group) has been met, according to results presented at the 25th United European Gastroenterology Week.
    • 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week.
    • 27 Jul 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top